ライフサイエンスコーパス: lymphangiogenesis

1 clusively by sprouting from embryonic veins (lymphangiogenesis).

2 es new lymphatic vessel growth (inflammatory lymphangiogenesis).

3 rats 1 day after surgery to induce meningeal lymphangiogenesis.

4 metriotic cells and contributes to increased lymphangiogenesis.

5 , paricalcitol showed markedly reduced renal lymphangiogenesis.

6 rsely, an excess of VEGF-C induced meningeal lymphangiogenesis.

7 mors prevents pulmonary metastasis and tumor lymphangiogenesis.

8 rare lymphatic vessels suggestive of limited lymphangiogenesis.

9 nd galectin-8 inhibitors reduce inflammatory lymphangiogenesis.

10 larisation model was used to induce hem- and lymphangiogenesis.

11 iated with increased lymphatic clearance and lymphangiogenesis.

12 cal role of macrophages in the regulation of lymphangiogenesis.

13 g protein, galectin-8, promotes pathological lymphangiogenesis.

14 rogression, concomitant with increased tumor lymphangiogenesis.

15 and VEGF-C production and exhibited aberrant lymphangiogenesis.

16 and metastasis by blocking angiogenesis and lymphangiogenesis.

17 esis, implicating arteries as drivers of gut lymphangiogenesis.

18 teraction between Tbx1 and Vegfr3 in cardiac lymphangiogenesis.

19 ury are observed in IBD along with increased lymphangiogenesis.

20 uring involution coincides with inflammatory lymphangiogenesis.

21 C) is a secreted growth factor essential for lymphangiogenesis.

22 lockade completely ablates TNF-alpha-induced lymphangiogenesis.

23 tumor cells and activation of VEGFC-induced lymphangiogenesis.

24 cer metastasis and correlated with decreased lymphangiogenesis.

25 ing by IC might induce VEGF-A and lymph node lymphangiogenesis.

26 ay, which is critical in embryonic and adult lymphangiogenesis.

27 markedly and significantly influenced tumor lymphangiogenesis.

28 at fibroblast growth factor 2 (FGF2) induces lymphangiogenesis.

29 factor for driving both tumor and lymph node lymphangiogenesis.

30 inoic acid (RA) concentration, in regulating lymphangiogenesis.

31 kers has advanced our understanding of tumor lymphangiogenesis.

32 ic cells, and lymphocytes are known to drive lymphangiogenesis.

33 L1R1 receptor activation by IL-1beta induced lymphangiogenesis.

34 th factor C (VEGF-C), is a major mediator of lymphangiogenesis.

35 (Adm) gene dosage within tumor cells affects lymphangiogenesis.

36 oncurrent suppression of hemangiogenesis and lymphangiogenesis.

37 regulator in developmental and inflammatory lymphangiogenesis.

38 s (LEC) toward guidance cues is critical for lymphangiogenesis.

39 ng points and increased inflammation-induced lymphangiogenesis.

40 role for this microRNA during developmental lymphangiogenesis.

41 nflammatory mediators and VEGFD during tumor lymphangiogenesis.

42 ctor receptor-3 (VEGFR3) signalling promotes lymphangiogenesis.

43 m to identify new candidate genes regulating lymphangiogenesis.

44 by promoting tissue fibrosis and inhibiting lymphangiogenesis.

45 alue in diseases accompanied by pathological lymphangiogenesis.

46 CoA for epigenetic modifications critical to lymphangiogenesis.

47 n studies, blocking antibodies revealed that lymphangiogenesis 14 days after bleomycin treatment was

48 MI induced robust, intramyocardial capillary lymphangiogenesis, adverse remodeling of epicardial prec

49 Analysis of lymphangiogenesis after full-thickness skin excision, a

50 th, motility, invasion, and tumor-associated lymphangiogenesis, all of which are also increased in pr

51 Lymphangiogenesis also contributes to the drainage of CN

52 strate for the first time that physiological lymphangiogenesis also occurs in primarily avascular sit

53 The blockade of lymphangiogenesis also resulted in accumulation of the c

54 ntial therapeutic tool for the modulation of lymphangiogenesis and angiogenesis in a variety of disea

55 gs and lymph nodes by inhibiting TCM-induced lymphangiogenesis and angiogenesis in the pre-metastatic

56 of CCBE1 into mouse skeletal muscle enhanced lymphangiogenesis and angiogenesis induced by adeno-asso

57 Overexpression of Adm increased lymphangiogenesis and cardiac function post-myocardial i

58 een measured in colorectal tumors undergoing lymphangiogenesis and correlated with metastasis.

59 herefore to analyze the effects of TGFBIp on lymphangiogenesis and determine whether TGFBIp-related l

60 actor VEGF-D promotes metastasis by inducing lymphangiogenesis and dilatation of the lymphatic vascul

61 hermore, local treatment with IL-10 promoted lymphangiogenesis and faster egress of macrophages from

62 erived factor that drives reparative cardiac lymphangiogenesis and function via Cx43, and this repres

63 a, while overexpression of sVEGFR-3 inhibits lymphangiogenesis and hemangiogenesis in a murine suture

64 duced by VEGF-C. sVEGFR-3 knockdown leads to lymphangiogenesis and hemangiogenesis in the mouse corne

65 This observation suggests a novel program of lymphangiogenesis and identifies a property of lymphatic

66 tion resulted in VEGF-A-dependent intranodal lymphangiogenesis and increased DC number.

67 y FOXC1 and FOXC2 as essential regulators of lymphangiogenesis and indicate a new potential mechanist

68 hway is regarded as the principal inducer of lymphangiogenesis and it contributes to metastases; howe

69 of Adm in tumors induced sentinel lymph node lymphangiogenesis and led to an increased incidence of K

70 and tube formation in vitro, and facilitate lymphangiogenesis and LN metastasis in vivo according to

71 21-3p is closely correlated with peritumoral lymphangiogenesis and lymph node (LN) metastasis in CSCC

72 vidence that SEMA3F re-expression diminishes lymphangiogenesis and lymph node metastasis.

73 Whether lymphangiogenesis and lymph node-mediated immunity are i

74 ph flow is increased but without significant lymphangiogenesis and lymphangiectasia.

75 ew mechanisms and therapeutic strategies for lymphangiogenesis and lymphangiogenesis-related diseases

76 Here, we determined that enhancing lymphangiogenesis and lymphatic function reduces experim

77 l miR-221-3p transfers into HLECs to promote lymphangiogenesis and lymphatic metastasis via downregul

78 port that TNF-alpha markedly promotes tumour lymphangiogenesis and lymphatic metastasis.

79 s in Tnfr1(-/-) mice largely restores tumour lymphangiogenesis and lymphatic metastasis.

80 mor types, mainly through the stimulation of lymphangiogenesis and lymphatic metastasis.

81 TAMs) virtually eliminates TNF-alpha-induced lymphangiogenesis and lymphatic metastasis.

82 ing to molecular regulation of developmental lymphangiogenesis and lymphatic network assembly are not

83 is SECs express Prox1, a master regulator of lymphangiogenesis and lymphatic phenotypes.

84 vide evidence to support the hypothesis that lymphangiogenesis and lymphatic transport are compensato

85 Lymphangiogenesis and lymphatic vessel remodeling are co

86 -C and sVEGFR3 significantly decreased graft lymphangiogenesis and lymphoid Th1 cell frequencies as c

87 -derived LECs enhanced wound healing through lymphangiogenesis and lymphvasculogenesis.

88 VEGFC signaling via VEGFR3 promotes lymphangiogenesis and metastasis by orthotopic colorecta

89 W620 cancer cells dramatically reduced tumor lymphangiogenesis and metastasis.

90 along with other lymphatic diseases, such as lymphangiogenesis and obstructed lymphatic vessels.

91 Our findings link melanin synthesis with lymphangiogenesis and open new treatment options in lymp

92 al process that might contribute to aberrant lymphangiogenesis and persistent inflammation in the ski

93 Herein, we show that IL-10 modulates corneal lymphangiogenesis and resolution of inflammation.

94 of BC-induced lymphatic progenitors in tumor lymphangiogenesis and suggest molecular targets for thei

95 Insight into the regulatory mechanisms of lymphangiogenesis and the manner in which uncontrolled i

96 ted a strong correlation between peritumoral lymphangiogenesis and tumor dissemination.

97 we demonstrate the multifaceted dynamics of lymphangiogenesis and valvulogenesis associated with tra

98 thus provides an optimal tool to study both lymphangiogenesis and valvulogenesis upon a pathological

99 observed in patients with SLE; we found that lymphangiogenesis and VEGF-A were increased in the lymph

100 tron 13 junction increases sKDR (suppressing lymphangiogenesis) and decreases mbKDR (inhibiting heman

101 vascular development and adult angiogenesis, lymphangiogenesis, and arteriogenesis.

102 lammation, fibroadipose deposition, impaired lymphangiogenesis, and dysfunctional lymphatic pumping.

103 organs show marked neoangiogenesis, aberrant lymphangiogenesis, and extensive induction of high endot

104 nts, which include glial scarring, meningeal lymphangiogenesis, and increased glymphatic activity.SIG

105 o inflammation, lymphatic vessel remodeling, lymphangiogenesis, and lipid and small molecule transpor

106 1-3p expression, lymphatic VASH1 expression, lymphangiogenesis, and LN metastasis in CSCC patients.

107 ammatory circuits that promote angiogenesis, lymphangiogenesis, and metastasis, both at local sites a

108 s and other BMDCs that promote angiogenesis, lymphangiogenesis, and metastasis.

109 F-C and VEGFR-3 as critical regulators of SC lymphangiogenesis, and provide a basis for further studi

110 orpholino-inhibited corneal angiogenesis and lymphangiogenesis, and suppressed graft rejection after

111 ranuloma access to secondary lymph organs by lymphangiogenesis, and that this process facilitates the

112 and mouse, one that forms through sprouting lymphangiogenesis, and the other by coalescence of isola

113 mplex virus keratitis, corneal pathology and lymphangiogenesis are ameliorated in Lgals8(-/-) mice.

114 Angiogenesis and lymphangiogenesis are crucial for cancer progression, pa

115 Controlled angiogenesis and lymphangiogenesis are essential for tissue development,

116 Inflammation and lymphangiogenesis are two cohesively coupled processes t

117 Presently, effects of VitD on lymphangiogenesis are unknown.

118 downregulation in CXCL14-expressing CAF and lymphangiogenesis as a novel component of CXCL14-promote

119 DK levels, which, appear to enhance both the lymphangiogenesis as the intrinsic aggressiveness of CM

120 ne receptor pairs that are involved in tumor lymphangiogenesis associated with lymph node metastasis.

121 treatment led to secondary corneal hem- and lymphangiogenesis associated with significant upregulati

122 Lymphangiogenesis associated with tertiary lymphoid stru

123 These results suggest that lymphangiogenesis associates with fibrosis through the T

124 on for 2 weeks before mating blocked ovarian lymphangiogenesis at all stages of follicle maturation,

125 distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions.

126 olecular level or how this process regulates lymphangiogenesis, because these complex molecular inter

127 ial cells; they show that sVEGFR-3 modulates lymphangiogenesis by impounding vascular endothelial gro

128 Inhibition of aGVHD-associated lymphangiogenesis by monoclonal antibodies against vascu

129 Cardiac lymphangiogenesis contributes to the reparative process

130 stitial fluid homeostasis, and dysfunctional lymphangiogenesis contributes to various pathological pr

131 Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis.

132 esothelial retinoic acid signaling regulates lymphangiogenesis, contributing to the niche properties.

133 EGF-D expression, deepening understanding of lymphangiogenesis control during tumor formation.

134 Tumor-associated lymphangiogenesis correlates with lymph node metastasis

135 Manipulation of meningeal lymphangiogenesis could be a new therapeutic strategy fo

136 role in cancer metastasis and inhibition of lymphangiogenesis could be valuable in fighting cancer d

137 Enhancing adipose tissue lymphangiogenesis could, therefore, improve metabolism i

138 In addition to lymphangiogenesis, COX-2 inhibition reduces many of the

139 istical difference in terms of angiogenesis, lymphangiogenesis, deposition of extracellular matrix, c

140 se data suggest that the function of Pdpn in lymphangiogenesis does not depend on threonine 34 in the

141 ogenesis inhibits liver metastasis, yet anti-lymphangiogenesis does not impact liver metastasis despi

142 ipo-VD) to stimulate adipose tissue-specific lymphangiogenesis during 16-week high-fat diet-induced o

143 e and likely synergize with VEGFA in corneal lymphangiogenesis during acute HSV-1 infection.

144 ontrast, meningeal lymphatics do not undergo lymphangiogenesis during EAE, suggesting heterogeneity i

145 tor (CLR) are implicated in angiogenesis and lymphangiogenesis during embryogenesis and wound healing

146 The observed lymphangiogenesis during infection was reduced by inhibi

147 on by promoting VEGF-A production and, thus, lymphangiogenesis during infection.

148 lar and cellular link between hemostasis and lymphangiogenesis during wound healing and reveal that V

149 of extradural electrodes provokes meningeal lymphangiogenesis, enhanced glymphatic influx of CSF, an

150 nal cord injury and VEGF-C-induced vertebral lymphangiogenesis exacerbates the inflammatory responses

151 etion in mouse embryos results in failure of lymphangiogenesis, fluid accumulation in tissues, and le

152 response to cutaneous wounding, but enhances lymphangiogenesis following both dermal wounding and inf

153 Experimental approaches aimed at boosting lymphangiogenesis following myocardial infarction in mic

154 atrix (MMP7, 9 and TIMP-1), angiogenesis and lymphangiogenesis for AR compared with healthy controls.

155 ound healing and tissue repair, pathological lymphangiogenesis has been implicated in a number of chr

156 Interestingly, stimulation of lymphangiogenesis has been shown to improve cardiac func

157 ic tissue transplantation, the inhibition of lymphangiogenesis has been successfully used to attenuat

158 une responses, and inflammation, the role of lymphangiogenesis has not been investigated during allog

159 age and suggest that treatments to stimulate lymphangiogenesis have promise for improving graft outco

160 dence indicates that inflammation-associated lymphangiogenesis (IAL) is not merely an endpoint event,

161 alginate microparticles, accelerated cardiac lymphangiogenesis in a dose-dependent manner and limited

162 So far, a physiological role for lymphangiogenesis in a primarily avascular site such as

163 ic vessels near the cribriform plate undergo lymphangiogenesis in a VEGFC - VEGFR3 dependent manner d

164 odoplanin(+) vessels, suggesting the lack of lymphangiogenesis in AMD and uveitis.

165 , mesenteric lymph node lymphadenopathy, and lymphangiogenesis in both the mesentery and mucosa.

166 intimate interplay between inflammation and lymphangiogenesis in cancer metastasis, and propose ther

167 d glycoproteins that induce angiogenesis and lymphangiogenesis in cancer, thereby promoting tumor gro

168 We therefore sought to address the role of lymphangiogenesis in CLAD.

169 veloping protein-based therapeutics to drive lymphangiogenesis in clinical settings, such as lymphede

170 To investigate lymphangiogenesis in CNV, we generated CNV in animals by

171 l and highlighting the clinical relevance of lymphangiogenesis in corneal fluid homeostasis.

172 blood and lymphatic vessels, but the role of lymphangiogenesis in CRC progression has not been determ

173 rowth factor C (VEGF-C) is a major driver of lymphangiogenesis in embryos and adults.

174 s and pregnancy, as well as the necessity of lymphangiogenesis in follicle maturation and health, are

175 however, the molecular mechanisms underlying lymphangiogenesis in HNSCC is still poorly understood.

176 Reduced lymphangiogenesis in IL-10(-/-) and lysozyme M Cre Stat3

177 helial growth factor-C and decreased corneal lymphangiogenesis in IL-10-deficient mice (IL-10(-/-)).

178 extualize the roles of lymphatic vessels and lymphangiogenesis in immunobiology, the impact immunosup

179 We conclude that aGVHD is associated with lymphangiogenesis in intestinal lesions and in lymph nod

180 the relationship between clot formation and lymphangiogenesis in mice, we find that platelets accele

181 actor receptor 3 (VEGFR-3) antibody to block lymphangiogenesis in mice.

182 dipose VEGF-D overexpression induced de novo lymphangiogenesis in murine adipose tissue, and obese Ad

183 rsus-host disease (aGVHD) is associated with lymphangiogenesis in murine allo-HSCT models as well as

184 Molecular regulation of TLO LVs differs from lymphangiogenesis in ontogeny with a dependence on cytok

185 contribute to UFF, but little is known about lymphangiogenesis in patients with UFF and peritonitis.

186 Moreover, the peptide inhibits lymphangiogenesis in primary tumors.

187 he lymphatic vasculature undergoes extensive lymphangiogenesis in response to a cryoinjury.

188 ycle of inflammation, COUP-TFII, VEGF-C, and lymphangiogenesis in the endometriotic microenvironment,

189 n, scavenging VEGF-C and VEGF-D, the role of lymphangiogenesis in the generation of an inflammatory r

190 Lymphangiogenesis in the meninges and altered glymphatic

191 and metastasis by blocking angiogenesis and lymphangiogenesis in the pre-metastatic organs as well a

192 lying the electrodes and extensive meningeal lymphangiogenesis in the surrounding dura.

193 ength and volume of both hemangiogenesis and lymphangiogenesis in the suture-induced corneal angiogen

194 CIS growth, motility and invasion as well as lymphangiogenesis in the tumor microenvironment.

195 istration of neutralizing Ab to IL-6 blocked lymphangiogenesis in TNF-alpha(-/-) mice.

196 ontaining protein 1 (CCBE1) is essential for lymphangiogenesis in vertebrates and has been associated

197 as active as wild-type Pdpn-Fc in inhibiting lymphangiogenesis in vitro and also inhibited lymphangio

198 9-cis RA promotes lymphangiogenesis in vitro and in vivo and has promise a

199 rm of the protein, Pdpn-Fc, leads to reduced lymphangiogenesis in vitro and in vivo.

200 Macrophage-dependent lymphangiogenesis in vitro was triggered upon inflammaso

201 e levels significantly increased peritumoral lymphangiogenesis in vivo and promoted the trans-differe

202 ic effects in vitro and is able to attenuate lymphangiogenesis in vivo.

203 promotes LEC collapse and potently inhibits lymphangiogenesis in vivo.

204 ymphangiogenesis in vitro and also inhibited lymphangiogenesis in vivo.

205 udy uncovers a unique molecular mechanism of lymphangiogenesis in which galectin-8-dependent crosstal

206 We propose a dual origin of gut lymphangiogenesis in which prior arterial growth is requ

207 Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types)

208 VEGF-C to induce lymphatic vessel expansion (lymphangiogenesis) in primary tumors and in draining sen

209 increased the knowledge of the mechanisms of lymphangiogenesis, including the roles of transcription

210 acromolecule, and immune cell clearance, and lymphangiogenesis increases this capability.

211 valves and can be used to study pathological lymphangiogenesis induced by various insults.

212 ng signaling through VEGFR-3 and suppressing lymphangiogenesis induced by VEGF-C. sVEGFR-3 knockdown

213 in vitro effectiveness of norcantharidin, a lymphangiogenesis inhibitor, as a potential co-adjuvant

214 d highly regulated model of angiogenesis and lymphangiogenesis involving vascular endothelial growth

215 Lymphangiogenesis is a key component of various inflamma

216 signaling and suggest that VEGFR-2-dependent lymphangiogenesis is a mechanism that restricts tissue i

217 In oncology the inhibition of lymphangiogenesis is an established therapeutic concept

218 Lymphangiogenesis is an important physiological response

219 logeneic transplantation, galectin-8-induced lymphangiogenesis is associated with an increased rate o

220 Excessive lymphangiogenesis is associated with cancer progression

221 Tumor lymphangiogenesis is associated with increased immune su

222 Indeed, inflammation-associated lymphangiogenesis is critical in resolving acute and chr

223 Lymphangiogenesis is critically involved in tissue fluid

224 immunization or contact hypersensitization, lymphangiogenesis is decreased and local inflammation is

225 Lymphangiogenesis is essential for fluid homeostasis in

226 genesis and determine whether TGFBIp-related lymphangiogenesis is important for the metastasis of tum

227 Lymphangiogenesis is induced via vascular endothelial gr

228 nic organ failure in kidney transplantation, lymphangiogenesis is not altered in CLAD patients.

229 iating LEC migration during tumor-associated lymphangiogenesis is not well defined.

230 rucial for cancer progression, particularly, lymphangiogenesis is pivotal for metastasis in breast ca

231 However, the role of TGFBIp signaling in lymphangiogenesis is poorly understood.

232 Endogenous regulation of lymphangiogenesis is poorly understood.

233 Pdpn(-/-) mice; likewise, galectin-8-induced lymphangiogenesis is reduced in Pdpn(-/-) mice.

234 Together, these studies reveal that lymphangiogenesis is regulated by two distinct proteolyt

235 Mechanistically, VEGF-C-induced lymphangiogenesis is significantly reduced in the Lgals8

236 that lipopolysaccharide-induced inflammatory lymphangiogenesis is strongly promoted by myeloid-derive

237 Lymphangiogenesis is supported by 2 homologous VEGFR3 li

238 cytokine, in the regulation of inflammatory lymphangiogenesis is undetermined.

239 Lymphangiogenesis is upregulated during incidents of tra

240 lted in significant hemangiogenesis (HA) and lymphangiogenesis (LA), while that of the whole limbus y

241 -associated corneal hemangiogenesis (HA) and lymphangiogenesis (LA).

242 with insufficient lymphatic function and/or lymphangiogenesis leading to fluid accumulation and deve

243 thelial growth factor-C remarkably increased lymphangiogenesis, lymphatic function, and lymphatic end

244 lution window decreased normal mammary gland lymphangiogenesis, mammary tumor-associated lymphangioge

245 Moreover, our data reveal that therapeutic lymphangiogenesis may be a promising new approach for th

246 ally avascular cornea, however, pathological lymphangiogenesis mediates diseases like corneal transpl

247 We studied the role of the lymphangiogenesis mediator vascular endothelial growth f

248 Attenuation of lymphangiogenesis might represent a novel strategy to ta

249 We conclude that increased lymphangiogenesis near the cribriform plate can contribu

250 We conclude that robust lymphangiogenesis occurs in mouse lungs after M. pulmoni

251 ta indicate that physiologic COX-2-dependent lymphangiogenesis occurs in the postpartum mammary gland

252 the fabric of adipose tissue, the impact of lymphangiogenesis on tumor-associated adipose tissue (AT

253 rative state that is distinct from embryonic lymphangiogenesis or quiescent lymphatic vessels observe

254 The formation of new lymphatic vessels (lymphangiogenesis), or remodeling of existing lymphatics

255 injection significantly increased meningeal lymphangiogenesis (P = .035) and tracer dye uptake in th

256 tions in both physiological and pathological lymphangiogenesis, particularly in tumor metastasis, mak

257 Lymphangiogenesis peaked at 14 to 28 days after bleomyci

258 Lymphangiogenesis plays a pivotal role in diverse pathol

259 Together, our findings provide evidence that lymphangiogenesis plays an unexpectedly beneficial role

260 ivation of ERbeta inhibited angiogenesis and lymphangiogenesis, possibly mediated by impaired vascula

261 selective therapeutic stimulation of cardiac lymphangiogenesis post-MI.

262 e demonstrate that neutrophils contribute to lymphangiogenesis primarily by modulating vascular endot

263 lymphatic vessels develop luminal valves as lymphangiogenesis proceeds.

264 terized, it is not clear how or if increased lymphangiogenesis promotes disease.

265 findings confirm that tyrosinase is a novel lymphangiogenesis regulator in developmental and inflamm

266 apeutic strategies for lymphangiogenesis and lymphangiogenesis-related diseases at various stages and

267 giogenesis and open new treatment options in lymphangiogenesis-related diseases.

268 bility via VEGF receptor 2 (VEGFR2), whereas lymphangiogenesis signals are transduced by VEGFC/D via

269 factor (VEGF)-C/VEGF receptor-3 signaling in lymphangiogenesis, significant new insights were obtaine

270 Augmenting VEGF-D signaling and lymphangiogenesis specifically in adipose tissue, theref

271 Moreover, CCBE1 was required for in vivo lymphangiogenesis stimulated by VEGFC but not VEGFD.

272 factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis.

273 Despite roles in pathological neo-lymphangiogenesis, the characterization of an endogenous

274 Lymphangiogenesis, the growth of lymphatic vessels, is e

275 F)-D is capable of inducing angiogenesis and lymphangiogenesis through signaling via VEGF receptor (V

276 VEGFR-3-mediated lymphangiogenesis thus appears to modulate the folliculo

277 lymphangiogenesis, mammary tumor-associated lymphangiogenesis, tumor cell invasion into lymphatics,

278 promotes tumor cell invasion on collagen and lymphangiogenesis via activation of beta1-integrin recep

279 10 indirectly regulates inflammatory corneal lymphangiogenesis via macrophages.

280 Pharmacological blockade of lymphangiogenesis via VEGFR-3 inhibition results in incr

281 Meningeal lymphangiogenesis was also evident in mice prepared with

282 Reduced lymphangiogenesis was also observed in the nonrelated me

283 Sprouting lymphangiogenesis was evident at 7 days.

284 The effect of IL-10 on lymphangiogenesis was indirect via macrophages, because

285 Widespread lymphangiogenesis was observed after bleomycin treatment

286 Peritumoral lymphangiogenesis was present in the ciliary body in uve

287 In rodents, mammary lymphangiogenesis was upregulated during weaning-induced

288 transplantation, graft hemeangiogenesis and lymphangiogenesis were evaluated by immunohistochemistry

289 Neutrophil aggregation and suppressed lymphangiogenesis were evident in the soft tissue at 21

290 l stage of vascular remodeling and sprouting lymphangiogenesis were examined by comparing the effects

291 n ANG2-blocking antibody inhibited embryonic lymphangiogenesis, whereas endothelium-specific ANG2 ove

292 VEGF-C signaling through VEGFR-3 promotes lymphangiogenesis, which is a clinically relevant target

293 nflammation through VEGF-A-driven lymph node lymphangiogenesis, which is controlled by FcgammaRIIb.

294 eptor 2 (VEGFR-2) signaling pathway mediates lymphangiogenesis, which is critical for lesion resoluti

295 Accumulation of Tregs and lymph node lymphangiogenesis, which may influence the fate of metas

296 dpnT34A-Fc might be an improved inhibitor of lymphangiogenesis with fewer toxic side effects.

297 of VitD and the deleterious associations of lymphangiogenesis with renal disease, we here tested the

298 We found that stimulation of lymphangiogenesis with VEGF-C156S, a mutant form of VEGF

299 esized that other factors may be involved in lymphangiogenesis, with proinflammatory cytokines as the

300 antibody (Ab) blocked HSV-1-mediated corneal lymphangiogenesis within the first 5 days postinfection.